United States · FDA National Drug Code directory
Dexilant
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 64764-171_402fdd3a-6183-4a0d-85ac-61d4221fc921
- Product NDC
- 64764-171
- Form
- CAPSULE, DELAYED RELEASE
- Composition / generic term
- dexlansoprazole
- Labeler
- Takeda Pharmaceuticals America, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20100412
- Source listing expiry
- 20261231
Source-listed ingredients
- DEXLANSOPRAZOLE — 30 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 7 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-00) · 64764-171-00
- 5 BLISTER PACK in 1 TRAY (64764-171-01) / 4 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK · 64764-171-01
- 1 BOTTLE in 1 CARTON (64764-171-03) / 5 CAPSULE, DELAYED RELEASE in 1 BOTTLE · 64764-171-03
- 10 BLISTER PACK in 1 CARTON (64764-171-11) / 10 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK · 64764-171-11
- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-19) · 64764-171-19
- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-30) · 64764-171-30
- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-90) · 64764-171-90
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →